Lupin Limited
LUPIN (NSE)

629.40

28,609.55
Proj. ROE (%)
8.98
Proj. P/E (x)
24.39
Proj EV / EBITDA (x)
12.00
Proj. P/BV (x)
2.15
Proj. Revenue ( Cr.)
17,461.43

Stock View

HOLD
Share on
The average score for Lupin Limited stands at 3 against 4, three months back.

Lupin Limited is an India-based pharmaceutical company. The Company develops and commercializes a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in over 100 markets in the United States, India, South Africa, and across the Asia Pacific, Latin America, and others. It offers vitamins, minerals, supplements and neurological products. It has presence in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and nonsteroidal anti-inflammatory drug therapy segments. Its complex generics portfolio includes Filgrastim, Peg-Filgrastim, Etanercept and Albuterol, and others. Its biosimilar products include Filgrastim, Peg-Filgrastim and Etanercept. Its specialty products consist of Solosec and NaMuscla. Its over-the-counter products include Softovac, Lupizyme, Aptivate, Lupisafe, Be One and V-Bath, and others. It supplies APIs for anti-retroviral, anti-malarial and others.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.

Technical Data
50 DMA()
671.70
100 DMA ()
723.36
200 DMA ()
826.07
52 Weeks Range
583.00
1,191.55
Street View :-
Bearish
Open ZERO Brokerage Demat Account
Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity